Session » Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

Date: Sunday, November 5, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 671

A New Histological Index for Predicting a Decline in Kidney Function in Patients with Lupus Nephritis. a Mexican Cohort Study of 186 Patients with a Kidney Biopsy

9:00AM-11:00AM: Abstract Number: 681

A Panel of Lupus Biomarkers for the Monitoring of Systemic Lupus Erythematosus: Performance Characteristics in Distinct SLE Cohorts

9:00AM-11:00AM: Abstract Number: 680

Abnormalities in Complement System Are Related to Disease Severity in Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 720

Ambulatory Blood Pressure and Skin Sodium Concentrations in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 696

An ANA Screening Assay Containing Multiple Antigens Increases the Sensitivity and Specificity of ANA Testing By Indirect Immunofluorescence

9:00AM-11:00AM: Abstract Number: 685

Anti-C1q Antibodies and Disease Activity in a Multi-Ethnic Lupus Cohort

9:00AM-11:00AM: Abstract Number: 708

Anti-RNP/Sm Antibodies Plus Lupus Anticoagulant As Risk Factor for Thrombosis in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 684

ANTI-RO52 KDa and ANTI-RO60 KDa Analysis in Systemic LUPUS Erythematous Patients to Detect ANTI-RO False-Negatives

9:00AM-11:00AM: Abstract Number: 689

Apolipoprotein L1 Risk Variants Associate with Hypertension and Nephritis Progression Despite Lower dsDNA Titers in Ghanaian Systemic Lupus Erythematous Patients

9:00AM-11:00AM: Abstract Number: 688

Associations between Standard Serological Markers and Different Clinical Phenotypes in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 718

Atherosclerotic Vascular Events in a Multinational SLE Inception Cohort: Description and Predictive Risk Factors over a 17 Year Period

9:00AM-11:00AM: Abstract Number: 672

Baseline Hyperuricemia As a Predictive Value for Development of Lupus Nephritis in Premenopausal SLE Patients

9:00AM-11:00AM: Abstract Number: 673

Cell Bound Complement Activation Products Distinguish Systemic Lupus Erythematosus from Other Diseases Among Patients with High Antinuclear Antibody Titers and Normal Complement

9:00AM-11:00AM: Abstract Number: 709

Characteristics of Cardiac Diseases in Systemic Lupus Erythematosus and Risk Factors of Different Echocardiographic Features

9:00AM-11:00AM: Abstract Number: 662

Clinical Significance of Non-Albumin Proteinuria for Severity Assessment of Tubulointerstitial Inflammation in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 703

Clinical Value of Autoantibodies for Lupus Myelitis and Its Subtypes: A Systematic Review

9:00AM-11:00AM: Abstract Number: 682

Complement Activation in Peripheral Blood in Relation to Lupus, Antiphospholipid and Rheumatoid Arthritis Autoantibodies: Insights from Clinical Laboratory Evaluations

9:00AM-11:00AM: Abstract Number: 710

D-Dimer As an Early Marker in Patients with Lupus Mesenteric Vasculitis

9:00AM-11:00AM: Abstract Number: 704

Detection of dsDNA Antibodies By New Fluoroimmunoassay with Comparable Diagnostic Sensitivity and Specificity to Farr-Ria

9:00AM-11:00AM: Abstract Number: 695

Development of a Multimarker Model for the Detection of Systemic Lupus Erythematosus Based on New and Traditional Autoantibodies

9:00AM-11:00AM: Abstract Number: 722

Differential Diagnosis of Autoimmune Diseases, Outlier Detection Plus Subgrouping in Clinical Trials By High Content Autoantibody Profiling

9:00AM-11:00AM: Abstract Number: 679

Distinct Interferon Scores Are Separately Associated with Activity and Long Term Sequelae in SLE

9:00AM-11:00AM: Abstract Number: 707

Distinctive Features of Positive Anti-Cell Antibody Tests on HEp-2 Cells (HEp-2-ANA) in Patients with Non-Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 697

Does Erythrocyte Sedimentation Rate Reflect and Discriminate Flare from Infection in Systemic Lupus Erythematosus? Correlation with Clinical and Laboratory Parameters of Disease Activity

9:00AM-11:00AM: Abstract Number: 706

Elevated Erythrocyte Sedimentation Rate Among Obese Patients with SLE- Not Always a Marker of Disease Activity

9:00AM-11:00AM: Abstract Number: 686

Endothelial Dysfunction in Systemic Lupus Erythematosus Patients without Cardiovascular events and Risk Factors: Correlation with Microvascular Alterations and angiogenic t Cells

9:00AM-11:00AM: Abstract Number: 692

High Plasma Factor XIII Transglutaminase Activity Inversely Correlates with SLE Disease Activity Yet Associates with Higher Carotid Artery IMT and Low CD14+CD16+ Monocyte Levels

9:00AM-11:00AM: Abstract Number: 687

Homocysteine Levels Are Independently Associated with Damage Accrual in Systemic Lupus Erythematosus Patients (SLE)

9:00AM-11:00AM: Abstract Number: 674

Identification of IRAK4-Dependent Gene Signature As a Biomarker Candidate for IRAK4 Small-Molecule Inhibitor in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 676

Immunosignature Autoantibody Profiles Provide Mechanistic Insight into Systemic Lupus Erythematosus and Differentiation from Symptomatically Overlapping Diseases

9:00AM-11:00AM: Abstract Number: 699

Impact of Anti-RBP Antibodies on Disease Activity and Quality-of-Life in Immunosuppressant Naive Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 721

Improving the Quality of Care in Systemic Lupus Erythematosis (SLE) through Time-Structured, Information Technology-Enhanced, Quality Improvement Indicator-Driven Patient Management

9:00AM-11:00AM: Abstract Number: 723

Incidence and Variability of Cardiovascular Risk Factors in Female Lupus Patients: A 3-Year Follow-up

9:00AM-11:00AM: Abstract Number: 668

Is Uric Acid Level a Predictor of Long-Term Renal Outcome in Lupus Nephritis?

9:00AM-11:00AM: Abstract Number: 715

Long-Term Outcome of Demyelnating Syndrome in Systemic Lupus Erythematosus: A Longitudinal Study

9:00AM-11:00AM: Abstract Number: 713

Long-Term Outcomes in Prolonged Low Disease Activity Are Comparable to Complete Clinical Remission in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 665

Low Vitamin D Is Associated with End Stage Renal Disease in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 664

Low Vitamin D Is Associated with Thrombosis in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 719

Lupus Nephritis in Isolation or Accompanied By Extra-Renal Manifestations: Early Lessons from the Accelerating Medicines Partnership

9:00AM-11:00AM: Abstract Number: 670

Membrane Attack Complex (MAC) Deposition in Lupus Nephritis Is Associated with Hypertension and Poor Clinical Response to Treatment

9:00AM-11:00AM: Abstract Number: 712

Novel Electronic Health Record Method Reveals That dsDNA Antibody-Negative Systemic Lupus Erythematosus Is Associated with Pain, Sleep, and Mood Disorders

9:00AM-11:00AM: Abstract Number: 705

Optimization of a Cost-Effective Diagnostic ANA Algorithm

9:00AM-11:00AM: Abstract Number: 702

Positive Direct Coombs’ Test in the Absence of Hemolytic Anemia Predicts High Disease Activity and Poor Renal Response in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 711

Prevalence and Risk Factors of Depressive Disorders in Chinese Patients with Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 714

Prolonged Antimalarial Treatment Is Associated with Increased Risk for Elevated Myocardial Biomarkers in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 716

Prolonged Exposure to Antiphospholipid Antibodies Is Associated with Endothelial Dysfunction in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 717

Risk Factors for Neuropsychiatric Systemic Lupus Erythematosus and Its Recurrence

9:00AM-11:00AM: Abstract Number: 698

Selected Nailfold Videocapillaroscopy Changes Are Linked to SLE Onset in a Cohort of Uctd Subjects

9:00AM-11:00AM: Abstract Number: 691

Serum Anti-NR2 Has a Better Specificity Than Sensitivity in Diagnosing Neuropsychiatric Systemic Lupus Erythematosus (NPSLE)

9:00AM-11:00AM: Abstract Number: 694

Serum Wisteria Floribunda Agglutinin-Positive Mac-2-Binding Protein Can Reflect Systemic Lupus Erythematosus Activity

9:00AM-11:00AM: Abstract Number: 677

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Predicts the Development of Organ Damage over 5 Years in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

9:00AM-11:00AM: Abstract Number: 690

SSA Antibodies Are Associated with Valvular Abnormalities in SLE Patients without Clinical Cardiovascular Disease

9:00AM-11:00AM: Abstract Number: 678

Systemic Hypertension Is Associated with Presence of Vascular Injury on Lupus Nephritis Renal Biopsies: A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 683

The Presence of Anti-Ro and Anti-La Antibodies Is Associated with Tubulointerstitial Damage in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 693

The Utility of a Rise in Anti – Double Stranded DNA Antibodies for Predicting Disease Flares in Systemic Lupus Erythematosus. a Meta-Analysis

9:00AM-11:00AM: Abstract Number: 675

Tissue-Based Biomarkers in Cutaneous Lupus Erythematosus: Type I IFN Responsive Protein Mxa and a Marker for Lymphocytic Inflammation (CD45) Correlate with CLASI Cross-Sectionally and Longitudinally

9:00AM-11:00AM: Abstract Number: 669

Unbiased Screening of Urinary Protein Biomarkers for Glomerular Filtration Rate Normalization

9:00AM-11:00AM: Abstract Number: 667

Urinary Metabolomic Fingerprint As Diagnostic Biomarker for Clinical Significant Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 663

Urinary Tumor-Necrosis Factor-like Weak Inducer of Apoptosis Is an Important Biomarker for Renal Lupus

9:00AM-11:00AM: Abstract Number: 701

Variability in ICAP (International Consensus on ANA Patterns) Pattern Reporting in Testing for Antinuclear Antibodies (ANA) By Indirect Immunofluorescence Assay (IFA)

9:00AM-11:00AM: Abstract Number: 700

Variability in Method of Testing for Antinuclear Antibodies (ANA): A Survey of Participants in the College of American Pathologist’s (CAP) Proficiency Testing Program

9:00AM-11:00AM: Abstract Number: 666

Vitamin D Deficiency Is Associated with Increased Serum Cholesterol Among Patients with Systemic Lupus Erythematosus

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].